Apis Assay: Pioneering the pharmacogenomic passport at Citylabs
By Bruntwood SciTech
Proximity to world-class clinical partners is essential for revolutionising patient care for diagnostic development company Apis Assay.
Based at Citylabs 1.0, they are positioned just a five-minute walk from one of Europe's largest genetics departments at the Manchester University NHS Foundation Trust (MFT). This unmatched, thriving ecosystem empowers them to get straight into the weeds of clinical challenges and co-develop a groundbreaking 'pharmacogenomic passport' alongside NHS experts.
Our interconnected health tech campuses has helped them foster the collaborations needed to deliver state-of-the-art genetic testing to 60 million people across the country.
Discover more about their innovative diagnostic solutions at https://www.apisassay.com, or explore our world-class life sciences campus at Citylabs.
Apis is primarily a diagnostics and development company, but we also have a therapeutic strategy as well. I work in a very large genetics department, so it's one of the biggest genetics units in the whole of Europe. Over the last, uh, year or so, we've been working on a project called Devote.
In collaboration with the Devote program, we'll be developing a pharmacogenomic passport. So this assay aims to provide actionable genetic information at the point of prescribing. The tests that we have at the moment, they're okay, but we can do them much better, and that's where Apis comes in. They bring their expertise in to try and help us to develop and deliver much more state-of-the-art types of tests that work better for patients.
As our department is just 5 minutes' walk away from Apis, we're able to really get into the weeds of what are the issues, what are the blockers, and then we can move on some of those challenges much more quickly. We would eventually want to get to a point that every single person in this country has a genetic test - so that's 60 million people. So we've got to look at the most nimble, effective ways of doing that, and working in partnership with companies is going to be the way to do that.